alfuzosin

al-FYOO-zo-sin

Therapeutic Classification: urinary tract antispasmodics

Pharmacologic Classification: peripherally acting antiadrenergics

REMS

Management of symptomatic benign prostatic hyperplasia (BPH).

Selectively blocks alpha₁-adrenergic receptors in the lower urinary tract to relax smooth muscle in the bladder neck and prostate.

Therapeutic effects:

Increased urine flow and decreased symptoms of BPH.

Absorption: 49% absorbed following oral administration; food enhances absorption.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver via the CYP3A4 isoenzyme system; 11% excreted unchanged in urine.

Half-Life: 10 hr.

ROUTE	ONSET	PEAK	DURATION
PO-ER	within hr	8 hr	24 hr

Contraindicated in:

Hypersensitivity;
Moderate to severe hepatic impairment;
Concurrent use of strong CYP3A4 inhibitors;
Concurrent use of other alpha-adrenergic blocking agents;
Severe renal impairment.

Use Cautiously in:

Congenital or acquired QTc prolongation or concurrent use of other drugs known to prolong QTc;
Mild hepatic impairment;
Symptomatic hypotension;
Concurrent use of antihypertensive agents, phosphodiesterase type 5 inhibitors, or nitrates (↑ risk of postural hypotension);
Previous hypotensive episode with other medications;
Geri: Consider age-related changes in body mass and cardiac, renal, and hepatic function when prescribing in older adults.

CV: postural hypotension

Derm: TOXIC EPIDERMAL NECROLYSIS

EENT: intraoperative floppy iris syndrome

GI: abdominal pain, constipation, dyspepsia, nausea

GU: erectile dysfunction, priapism

Hemat: thrombocytopenia

Neuro: dizziness, fatigue, headache

Resp: bronchitis, pharyngitis, sinusitis

Drug-drug:

Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, and ritonavir, may significantly ↑ levels and risk of toxicity; concurrent use contraindicated.
Cimetidine, atenolol, and diltiazem may ↑ levels and risk of toxicity.
May ↑ levels and risk of toxicity of atenolol and diltiazem; monitor BP and heart rate.
↑risk of hypotension with antihypertensives, nitrates, phosphodiesterase type 5 inhibitors (including sildenafil, tadalafil, and vardenafil) and acute ingestion of alcohol.

PO (Adults ): 10 mg once daily.

(Generic available)

Extended-release tablets: 10 mg

Assess for symptoms of BPH (urinary hesitancy, feeling of incomplete bladder emptying, interruption of urinary stream, impairment of size and force of urinary stream, terminal urinary dribbling, straining to start flow, dysuria, urgency) before and periodically during therapy.
- Assess for orthostatic reaction and syncope. Monitor BP (lying and standing) and pulse frequently during initial dose adjustment and periodically thereafter. May occur within a few hr after initial doses and occasionally thereafter.
- Rule out prostatic carcinoma before therapy; symptoms are similar.

PO: Administer with food at the same meal each day. Tablets must be swallowed whole; DNC: do not crush, break, or chew.

Instruct patient to take medication with the same meal each day. Take missed doses as soon as remembered. If not remembered until next day, omit; do not double doses.
- May cause dizziness or drowsiness. Advise patient to avoid driving or other activities requiring alertness until response to the medication is known.
- Caution patient to avoid sudden changes in position to decrease orthostatic hypotension.
- Advise patient to consult health care professional before taking any cough, cold, or allergy remedies.
- Instruct patient to notify health care professional of medication regimen before any surgery, especially cataract surgery.
- Advise patient to notify health care professional if priapism, angina, frequent dizziness, rash, or fainting occurs.
- Emphasize the importance of follow-up exams to evaluate effectiveness of medication.
- Assess risk for falls; implement fall prevention program and instruct patient and family in preventing falls at home.

Decreased symptoms of BPH.

Uroxatral

Xatral

NDC Code

13668- Torrent Pharmaceuticals Limited
- 13668-021- ALFUZOSIN HYDROCHLORIDE
  - 13668-021-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (13668-021-01)

13668- Torrent Pharmaceuticals Limited
- 13668-021- ALFUZOSIN HYDROCHLORIDE
  - 13668-021-05- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (13668-021-05)

13668- Torrent Pharmaceuticals Limited
- 13668-021- ALFUZOSIN HYDROCHLORIDE
  - 13668-021-30- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (13668-021-30)

13668- Torrent Pharmaceuticals Limited
- 13668-021- ALFUZOSIN HYDROCHLORIDE
  - 13668-021-64- 90 TABLET, EXTENDED RELEASE in 1 DOSE PACK (13668-021-64)

29300- Unichem Pharmaceuticals (USA), Inc.
- 29300-155- Alfuzosin hydrochloride
  - 29300-155-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-155-01)

29300- Unichem Pharmaceuticals (USA), Inc.
- 29300-155- Alfuzosin hydrochloride
  - 29300-155-13- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-155-13)

29300- Unichem Pharmaceuticals (USA), Inc.
- 29300-155- Alfuzosin hydrochloride
  - 29300-155-19- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-155-19)

33261- Aidarex Pharmaceuticals LLC
- 33261-994- Alfuzosin Hydrochloride
  - 33261-994-30- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (33261-994-30)

33261- Aidarex Pharmaceuticals LLC
- 33261-994- Alfuzosin Hydrochloride
  - 33261-994-60- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (33261-994-60)

33261- Aidarex Pharmaceuticals LLC
- 33261-994- Alfuzosin Hydrochloride
  - 33261-994-90- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (33261-994-90)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-746- Alfuzosin Hydrochloride
  - 43353-746-30- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43353-746-30)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-746- Alfuzosin Hydrochloride
  - 43353-746-60- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43353-746-60)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-945- Alfuzosin hydrochloride
  - 43353-945-16- 6000 TABLET, EXTENDED RELEASE in 1 BOTTLE (43353-945-16)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-945- Alfuzosin hydrochloride
  - 43353-945-30- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (43353-945-30)

43353- Aphena Pharma Solutions - Tennessee, LLC
- 43353-945- Alfuzosin hydrochloride
  - 43353-945-60- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (43353-945-60)

47335- Sun Pharmaceutical Industries, Inc.
- 47335-956- Alfuzosin Hydrochloride
  - 47335-956-08- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-956-08)

47335- Sun Pharmaceutical Industries, Inc.
- 47335-956- Alfuzosin Hydrochloride
  - 47335-956-18- 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-956-18)

47335- Sun Pharmaceutical Industries, Inc.
- 47335-956- Alfuzosin Hydrochloride
  - 47335-956-81- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-956-81)

47335- Sun Pharmaceutical Industries, Inc.
- 47335-956- Alfuzosin Hydrochloride
  - 47335-956-83- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-956-83)

47335- Sun Pharmaceutical Industries, Inc.
- 47335-956- Alfuzosin Hydrochloride
  - 47335-956-88- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (47335-956-88)

55648- Wockhardt Limited
- 55648-738- Alfuzosin Hydrochloride
  - 55648-738-01- 30 TABLET in 1 BOTTLE (55648-738-01)

55648- Wockhardt Limited
- 55648-738- Alfuzosin Hydrochloride
  - 55648-738-02- 100 TABLET in 1 BOTTLE (55648-738-02)

55648- Wockhardt Limited
- 55648-738- Alfuzosin Hydrochloride
  - 55648-738-03- 500 TABLET in 1 BOTTLE (55648-738-03)

55648- Wockhardt Limited
- 55648-738- Alfuzosin Hydrochloride
  - 55648-738-05- 10 BLISTER PACK in 1 CARTON (55648-738-05) > 10 TABLET in 1 BLISTER PACK

57237- Rising Health, LLC
- 57237-114- Alfuzosin Hydrochloride
  - 57237-114-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (57237-114-01)

57237- Rising Health, LLC
- 57237-114- Alfuzosin Hydrochloride
  - 57237-114-05- 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (57237-114-05)

57237- Rising Health, LLC
- 57237-114- Alfuzosin Hydrochloride
  - 57237-114-90- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (57237-114-90)

59212- Concordia Pharmaceuticals Inc.
- 59212-200- Uroxatral
  - 59212-200-10- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (59212-200-10)

59212- Concordia Pharmaceuticals Inc.
- 59212-200- Uroxatral
  - 59212-200-30- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (59212-200-30)

60505- Apotex Corp.
- 60505-2850- Alfuzosin Hydrochloride
  - 60505-2850-0- 10 BLISTER PACK in 1 CARTON (60505-2850-0) > 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK

60505- Apotex Corp.
- 60505-2850- Alfuzosin Hydrochloride
  - 60505-2850-1- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-2850-1)

60505- Apotex Corp.
- 60505-2850- Alfuzosin Hydrochloride
  - 60505-2850-3- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-2850-3)

60505- Apotex Corp.
- 60505-2850- Alfuzosin Hydrochloride
  - 60505-2850-5- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-2850-5)

60505- Apotex Corp.
- 60505-2850- Alfuzosin Hydrochloride
  - 60505-2850-7- 8000 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-2850-7)

60505- Apotex Corp.
- 60505-2850- Alfuzosin Hydrochloride
  - 60505-2850-8- 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-2850-8)

63629- Bryant Ranch Prepack
- 63629-7907- Alfuzosin hydrochloride
  - 63629-7907-1- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (63629-7907-1)

64679- Wockhardt USA LLC.
- 64679-738- Alfuzosin Hydrochloride
  - 64679-738-01- 30 TABLET in 1 BOTTLE (64679-738-01)

64679- Wockhardt USA LLC.
- 64679-738- Alfuzosin Hydrochloride
  - 64679-738-02- 100 TABLET in 1 BOTTLE (64679-738-02)

64679- Wockhardt USA LLC.
- 64679-738- Alfuzosin Hydrochloride
  - 64679-738-03- 500 TABLET in 1 BOTTLE (64679-738-03)

64679- Wockhardt USA LLC.
- 64679-738- Alfuzosin Hydrochloride
  - 64679-738-05- 10 BLISTER PACK in 1 CARTON (64679-738-05) > 10 TABLET in 1 BLISTER PACK

65862- Aurobindo Pharma Limited
- 65862-249- Alfuzosin Hydrochloride
  - 65862-249-01- 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-249-01)

65862- Aurobindo Pharma Limited
- 65862-249- Alfuzosin Hydrochloride
  - 65862-249-05- 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-249-05)

65862- Aurobindo Pharma Limited
- 65862-249- Alfuzosin Hydrochloride
  - 65862-249-30- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-249-30)

65862- Aurobindo Pharma Limited
- 65862-249- Alfuzosin Hydrochloride
  - 65862-249-90- 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-249-90)

65862- Aurobindo Pharma Limited
- 65862-249- Alfuzosin Hydrochloride
  - 65862-249-99- 1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (65862-249-99)

69097- Cipla USA Inc.
- 69097-844- Alfuzosin Hydrochloride extended release
  - 69097-844-02- 30 TABLET in 1 BOTTLE (69097-844-02)

69097- Cipla USA Inc.
- 69097-844- Alfuzosin Hydrochloride extended release
  - 69097-844-05- 90 TABLET in 1 BOTTLE (69097-844-05)

69097- Cipla USA Inc.
- 69097-844- Alfuzosin Hydrochloride extended release
  - 69097-844-07- 100 TABLET in 1 BOTTLE (69097-844-07)

69097- Cipla USA Inc.
- 69097-844- Alfuzosin Hydrochloride extended release
  - 69097-844-12- 500 TABLET in 1 BOTTLE (69097-844-12)

70934- Denton Pharma, Inc. DBA Northwind Pharmaceuticals
- 70934-306- Alfuzosin Hydrochloride
  - 70934-306-30- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (70934-306-30)

76282- Exelan Pharmaceuticals Inc.
- 76282-302- Alfuzosin hydrochloride
  - 76282-302-01- 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (76282-302-01)

76282- Exelan Pharmaceuticals Inc.
- 76282-302- Alfuzosin hydrochloride
  - 76282-302-05- 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (76282-302-05)

76282- Exelan Pharmaceuticals Inc.
- 76282-302- Alfuzosin hydrochloride
  - 76282-302-90- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (76282-302-90)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Code ⬆